Quetiapine for the treatment of generalised anxiety disorder
Please note that following on from information provided to NICE by the company in February 2011, the appraisal of Quetiapine for the treatment of generalised anxiety disorder [ID347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 347
Referral date 01 June 2010
Topic area
  • Mental health and behavioural conditions
  • Public health

Provisional Schedule

Closing date for invited submissions / evidence submission: 9 December 2010
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: Liz Walker
Technical Lead: Raisa Sidhu

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
20 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in February 2011, the appraisal of Quetiapine for the treatment of generalised anxiety disorder [ID347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

For further information on our processes and methods, please see our CHTE processes and methods manual